

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis ID6578

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

At scoping it was highlighted that medicines including gelatine may not be acceptable for some people from certain religious backgrounds. Avapritinib does not include gelatine and so may be a suitable option for these people, in the place of other medicines which do include gelatine. The committee noted that the only existing treatment that has no gelatine-free formulation is midostaurin, a tyrosine kinase inhibitor, that is not considered a comparator.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

A stakeholder highlighted that avapritinib cannot be taken during pregnancy. The committee noted that pregnancy, religion and belief are protected under the Equality Act 2010. But because its recommendation does not restrict access to treatment for some people over others, the committee agreed there were no potential equalities issues.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No further equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendation affects all groups equally.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the recommendation affects all groups equally.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in section 3.19.

**Approved by Associate Director (name):** Ross Dent

**Date:** 19/05/2026

Technology appraisals: Guidance development

Equality impact assessment for the Health Technology Evaluation of Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis ID6578

Issue date: May 2026